The mechanism of inhibition of the influenza A virus M2 proton channel by the antiviral drug amantadine has been under intense investigation. The importance of a mechanistic understanding is heightened by the prevalence of amantadine-resistant mutations. To gain mechanistic insight at the molecular level, we carried out extensive molecular dynamics simulations of the tetrameric M2 proton channel in both apo and amantadine-bound forms in a lipid bilayer. The simulation of the apo form revealed that Val27 from the four M2 subunits can form a secondary gate near the channel entrance and break the water wire in the channel pore. This gate arises from physical occlusion and the elimination of hydrogen-bonding partners for water molecules. In the presence of amantadine, the secondary gate formed by Val27 and the drug molecule lying just below form an extended blockage, which breaks the water wire throughout the simulation. The location and orientation of amantadine inside of the channel pore as found in our simulation are supported by a host of experimental observations. Our study suggests a novel role for Val27 in the inhibition of the M2 proton channel by amantadine.The M2 protein of the influenza A virus is a tetrameric proton-selective ion channel activated by low pH, and its channel activity is essential for the life cycle of the virus. The antiviral drug amantadine inhibits the replication of the virus by putatively binding to the transmembrane domain (TMD) of the M2 proton channel. 1 However, over 90% of recent influenza A cases were found to have the S31N mutation on the M2 protein that confers amantadine resistance. 2 Along with experiments, 3-9 extensive computational studies [10][11][12][13][14][15][16][17] have been performed to model the structure of the M2 TMD and to understand the mechanisms of conductance and selectivity of the proton channel. The tetrad of H37 is part of the putative primary gate essential for channel conductance and selectivity. 5,9 The structure of M2 TMD when amantadine is present has been determined recently by solidstate NMR spectroscopy. 18 Here, we report a study aimed at modeling the binding of amantadine to M2 TMD. Our results present both mechanistic insight on the inhibition of M2 by amantadine and possible explanations for mutations leading to amantadine resistance.We modeled an amantadine molecule into the structure of M2 TMD determined in the presence of amantadine (PDB code 2h95; 18 see "Setup of Simulation Systems" and Figure S1 in Supporting Information). Amantadine was initially positioned around S31, in line with
NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript the central location of this residue in the constellation of amantadine-resistant mutations (on V27, A30, S31, and G34). 3 Parallel molecular dynamics simulations were then carried out for up to 15 ns on M2 TMD in the amantadine-bound form and in the apo form (the latter based on the apo structure found in PDB code 1nyj 19 ).We monitored the radii of the channel pores across...